Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 7/20 | 1.00 |
| ▸ | ATP4B | P51164 | 7/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | DAPK1 | P53355 | 3/20 | 0.43 |
| ▸ | MGMT | P16455 | 3/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2192249 | 0.99 | ATP4A (0.97) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL11005085 | 0.88 | ATP4A (0.78) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL10918911 | 0.86 | ATP4A (0.76) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL7984904 | 0.84 | ATP4A (0.73) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL11001197 | 0.84 | ATP4A (0.73) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL10918297 | 0.81 | ATP4A (0.68) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL10531597 | 0.80 | ATP4A (0.69) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL10919559 | 0.80 | ATP4A (0.67) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL2191144 | 0.80 | ATP4A (1.00) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL2193396 | 0.79 | ATP4A (0.67) | ATP4AATP4BL3MBTL1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3103437-B1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-12-20 | — | — | EP | claimed |
| US-20150086497-A1 | Skin Lightening Compositions | ELC MAN LLC (US) | 2015-03-26 | — | — | US | claimed |
| EP-0068378-B1 | NOVEL IMIDAZO(1,2-A)PYRIDINES AND PYRAZINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-03-05 | — | — | EP | claimed |
| US-4507294-A | TREATMENT OF PEPTIC ULCERS | SCHERING CORP. (US) | 1985-03-26 | — | — | US | claimed |
| EP-3103437-B1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2521531-B1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170035672-A1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-02-09 | — | — | US | disclosed |
| EP-3103437-A1 | SKIN LIGHTENING COMPOSITIONS | ELC Management LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9314415-B2 | Skin lightening compositions | ELC MANAGEMENT LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-8992897-B2 | Skin lightening compositions | ELC MANAGEMENT LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150086497-A1 | Skin Lightening Compositions | ELC MAN LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | NIKI YOKO (JP) | 2014-07-31 | — | — | US | disclosed |
| EP-1443934-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003041714-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
| WO-2001085167-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PROTON PUMP INHIBITORS AND GASTRIN/CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085724-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| EP-0339071-A1 | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989003833-A1 | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-05-05 | — | — | WO | disclosed |
| EP-0068378-B1 | NOVEL IMIDAZO(1,2-A)PYRIDINES AND PYRAZINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-03-05 | — | — | EP | disclosed |
| US-4507294-A | TREATMENT OF PEPTIC ULCERS | SCHERING CORP. (US) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885L3MBTL1 2878/4885 |
| US-20170035672-A1 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885L3MBTL1 2878/4885 |
| US-20150086497-A1 | Skin Lightening Compositions | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885L3MBTL1 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.